I have been long
LDOS since March 17th with a ½ size position. I have come close to being stopped out but, my stop never hit. I was up enough that I held through earnings on May 6th. I would expect that it could form a small handle on this cup base, but it may not.
I like the fact that it is above all the Moving Averages. I am not an expert at Fibonacci lines, but it looks like we are right at the .382 retracement area and what is a small resistance area as well. Once through that area, the 50% retrace aligns with another area of resistance. At around $160 – 165 a share.
They were upgraded to Overweight by Wells Fargo with a price target of $200.
If you like this idea, please make it your own so it aligns with your trading / investing plan.
Leidos Beat Expectations
Tuesday, May 6, 2025 at 6:00 AM ET
Leidos (LDOS) reported earnings of $2.97 per share on revenue of $4.25 billion for the first quarter ended March 2025. The consensus earnings estimate was $2.47 per share on revenue of $4.08 billion. The Earnings Whisper number was $2.54 per share. The company beat expectations by 16.93% while revenue grew 6.79% on a year-over-year basis.
The company said it continues to expect 2025 earnings of $10.35 to $10.75 per share on revenue of $16.90 billion to $17.30 billion. The current consensus earnings estimate is $10.51 per share on revenue of $17.09 billion for the year ending December 31, 2025.
Leidos Holdings Inc. is an applied technology company delivering solutions and services that leverage the power of data analytics, systems integration, and cybersecurity across three markets: national security, health, and engineering.
I like the fact that it is above all the Moving Averages. I am not an expert at Fibonacci lines, but it looks like we are right at the .382 retracement area and what is a small resistance area as well. Once through that area, the 50% retrace aligns with another area of resistance. At around $160 – 165 a share.
They were upgraded to Overweight by Wells Fargo with a price target of $200.
If you like this idea, please make it your own so it aligns with your trading / investing plan.
Leidos Beat Expectations
Tuesday, May 6, 2025 at 6:00 AM ET
Leidos (LDOS) reported earnings of $2.97 per share on revenue of $4.25 billion for the first quarter ended March 2025. The consensus earnings estimate was $2.47 per share on revenue of $4.08 billion. The Earnings Whisper number was $2.54 per share. The company beat expectations by 16.93% while revenue grew 6.79% on a year-over-year basis.
The company said it continues to expect 2025 earnings of $10.35 to $10.75 per share on revenue of $16.90 billion to $17.30 billion. The current consensus earnings estimate is $10.51 per share on revenue of $17.09 billion for the year ending December 31, 2025.
Leidos Holdings Inc. is an applied technology company delivering solutions and services that leverage the power of data analytics, systems integration, and cybersecurity across three markets: national security, health, and engineering.
Ideas I publish are my own. They are not meant to be investment / trading advice. You are encouraged to do your own due diligence.
I may or may not take any trade published and I am under no obligation to post any action or update to any idea.
I may or may not take any trade published and I am under no obligation to post any action or update to any idea.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Ideas I publish are my own. They are not meant to be investment / trading advice. You are encouraged to do your own due diligence.
I may or may not take any trade published and I am under no obligation to post any action or update to any idea.
I may or may not take any trade published and I am under no obligation to post any action or update to any idea.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.